237 related articles for article (PubMed ID: 30107134)
21. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
22. Effects of protein-protein interface disruptors at the ligand of the glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR).
Platania CBM; Ronchetti S; Riccardi C; Migliorati G; Marchetti MC; Di Paola L; Lazzara F; Drago F; Salomone S; Bucolo C
Biochem Pharmacol; 2020 Aug; 178():114110. PubMed ID: 32569630
[TBL] [Abstract][Full Text] [Related]
23. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
24. GITR Blockade Facilitates Treg Mediated Allograft Survival.
Sonawane SB; Kim JI; Lee MK; Lee SH; Duff PE; Moore DJ; Lian MM; Deng S; Choi Y; Yeh H; Caton AJ; Markmann JF
Transplantation; 2009 Nov; 88(10):1169-77. PubMed ID: 19935370
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions.
Baltz KM; Krusch M; Bringmann A; Brossart P; Mayer F; Kloss M; Baessler T; Kumbier I; Peterfi A; Kupka S; Kroeber S; Menzel D; Radsak MP; Rammensee HG; Salih HR
FASEB J; 2007 Aug; 21(10):2442-54. PubMed ID: 17360848
[TBL] [Abstract][Full Text] [Related]
26. GITR Activation Positively Regulates Immune Responses against Toxoplasma gondii.
Costa FR; Mota CM; Santiago FM; Silva MV; Ferreira MD; Fonseca DM; Silva JS; Mineo JR; Mineo TW
PLoS One; 2016; 11(3):e0152622. PubMed ID: 27027302
[TBL] [Abstract][Full Text] [Related]
27. Biological role of GITR/GITRL in attributes and immune responses of macrophage.
Fu Z; Wang S; Li J; Zhang Y; Li H; Li G; Wan X; Zhang Y
J Leukoc Biol; 2020 Feb; 107(2):309-321. PubMed ID: 31833599
[TBL] [Abstract][Full Text] [Related]
28. Simultaneously increased expression of glucocorticoid‑induced tumor necrosis factor receptor and its ligand contributes to increased interleukin‑5/13‑producing group 2 innate lymphocytes in murine asthma.
Zhang M; Wan J; Xu Y; Zhang D; Peng J; Qi C; Guo Q; Xia S; Su Z; Wang S; Xu H
Mol Med Rep; 2017 Jun; 15(6):4291-4299. PubMed ID: 28440511
[TBL] [Abstract][Full Text] [Related]
29. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily.
Nocentini G; Riccardi C
Eur J Immunol; 2005 Apr; 35(4):1016-22. PubMed ID: 15770698
[TBL] [Abstract][Full Text] [Related]
30. Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis.
Li Y; Yang S; Li Z; Meng H; Jin W; Yang H; Yin W
J Transl Med; 2019 May; 17(1):168. PubMed ID: 31118027
[TBL] [Abstract][Full Text] [Related]
31. Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.
You S; Poulton L; Cobbold S; Liu CP; Rosenzweig M; Ringler D; Lee WH; Segovia B; Bach JF; Waldmann H; Chatenoud L
PLoS One; 2009 Nov; 4(11):e7848. PubMed ID: 19936238
[TBL] [Abstract][Full Text] [Related]
32. Anti-GITR agonist therapy intrinsically enhances CD8 T cell responses to chronic lymphocytic choriomeningitis virus (LCMV), thereby circumventing LCMV-induced downregulation of costimulatory GITR ligand on APC.
Clouthier DL; Zhou AC; Watts TH
J Immunol; 2014 Nov; 193(10):5033-43. PubMed ID: 25281716
[TBL] [Abstract][Full Text] [Related]
33. Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system.
Kobayashi Y; Kiguchi N; Fukazawa Y; Saika F; Maeda T; Kishioka S
J Biol Chem; 2015 May; 290(20):12603-13. PubMed ID: 25787078
[TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
35. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity.
Kamimura Y; Iwai H; Piao J; Hashiguchi M; Azuma M
J Immunol; 2009 Mar; 182(5):2708-16. PubMed ID: 19234165
[TBL] [Abstract][Full Text] [Related]
36. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Shevach EM; Stephens GL
Nat Rev Immunol; 2006 Aug; 6(8):613-8. PubMed ID: 16868552
[TBL] [Abstract][Full Text] [Related]
37. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
38. Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells.
Yu KY; Kim HS; Song SY; Min SS; Jeong JJ; Youn BS
Biochem Biophys Res Commun; 2003 Oct; 310(2):433-8. PubMed ID: 14521928
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
[TBL] [Abstract][Full Text] [Related]
40. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
